SCHEMBL22648265

SCHEMBL22648265

O=C1CCOCCN1CCCNc1nc(Cl)ncc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 1/20 0.47
ULK2 Q8IYT8 1/20 0.47
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 4/20 0.42
HSD17B10 Q99714 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
STK17B O94768 2/20 0.41
STK17A Q9UEE5 2/20 0.41
PGK1 P00558 1/20 0.40
PDE4B Q07343 3/20 0.39
PDE4A P27815 2/20 0.39
PDE4D Q08499 2/20 0.39
MAPT P10636 2/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38
GFER P55789 1/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22648429 0.89 ULK1 (0.43) ULK1ULK2ALDH1A1KDM4EHSD17B10
SCHEMBL22648277 0.86 TBK1 (0.45) ULK1ULK2ALDH1A1KDM4EHSD17B10
SCHEMBL25008208 0.86 ULK1 (0.58) ULK1ULK2ALDH1A1KDM4EHSD17B10
SCHEMBL1917052 0.86 ALDH1A1 (0.54) ALDH1A1KDM4EHSD17B10SMN1; SMN2LMNA
SCHEMBL3337053 0.86 ALDH1A1 (0.54) ALDH1A1KDM4EHSD17B10SMN1; SMN2LMNA
SCHEMBL22648409 0.85 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10SMN1; SMN2LMNA
SCHEMBL22635407 0.84 ALDH1A1 (0.50) ALDH1A1KDM4EHSD17B10SMN1; SMN2LMNA
SCHEMBL22648377 0.83 ALDH1A1 (0.41) ULK1ULK2ALDH1A1KDM4EHSD17B10
SCHEMBL22652121 0.80 ULK1 (0.44) ULK1ULK2ALDH1A1KDM4EHSD17B10
SCHEMBL22648316 0.79 IRAK4 (0.42) ALDH1A1KDM4EHSD17B10SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3966207-B1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS LLC (US) 2023-11-01 EP disclosed
EP-3966206-B1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS LLC (US) 2023-08-09 EP disclosed
US-20230047915-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-02-16 US disclosed
US-20230039712-A1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-02-09 US disclosed
US-11530206-B2 Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2022-12-20 US disclosed
US-11518758-B2 Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2022-12-06 US disclosed
WO-2020231808-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2020-11-19 WO disclosed
US-20200354352-A1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2020-11-12 US disclosed
US-20200354346-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2020-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039712-A1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 ULK1 4/4885ULK2 9/4885ALDH1A1 2271/4885
US-20230047915-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 ULK1 4/4885ULK2 8/4885ALDH1A1 2874/4885
US-11530206-B2 Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof BECN1, SQSTM1, ATG7 ULK1 4/4885ULK2 9/4885ALDH1A1 2271/4885
US-20200354352-A1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 ULK1 4/4885ULK2 9/4885ALDH1A1 2271/4885
US-20200354346-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 ULK1 4/4885ULK2 8/4885ALDH1A1 2874/4885
US-11518758-B2 Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof BECN1, SQSTM1, ATG7 ULK1 4/4885ULK2 8/4885ALDH1A1 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.